Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Peripheral blood TCR marker for liver cancer as well as detection kit and application thereof

A marker and peripheral blood technology, applied in the field of genetic testing, can solve the problems of large workload required for testing, limitations of early tumor diagnosis, pain and injury to patients, etc., and achieves easy sampling, reduced testing costs, and low labor costs. Effect

Pending Publication Date: 2020-09-04
CHENGDU EXAB BIOTECH CO LTD
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0029] For patients with ascites, liver cancer exfoliated cells can be detected, which is highly sensitive to tumor detection, but there are some problems: some benign cells may be misread as cancer cells when they are abnormally shaped; cancer cells detected in ascites cannot be detected. Tumor positioning; in order to ensure reliability, the workload required for detection is large; extracting ascites is more painful and harmful to patients, etc.
However, this method is more suitable for the guidance of treatment, and has considerable limitations for the diagnosis of early tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peripheral blood TCR marker for liver cancer as well as detection kit and application thereof
  • Peripheral blood TCR marker for liver cancer as well as detection kit and application thereof
  • Peripheral blood TCR marker for liver cancer as well as detection kit and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Through immunographic analysis, the liver cancer TCR marker CDR3 sequence set was obtained:

[0077] 1. Sampling and immune map analysis

[0078] Collect 1301 control groups (including healthy people and patients with non-tumor diseases, 1300 people for model building, 1 healthy person for verification), 11 liver cancer patients (10 people for model building, 1 person for verification) and Peripheral blood (10mL per person) of a subject with unknown health status, through high-throughput sequencing to obtain the amino acid sequence of the epitope 3 (CDR3) of the TCR of the subject and the control group, to ensure the functional TCR of each sample The total number of CDR3 sequences should not be less than 30,000;

[0079] 2. The CDR3 sequence of the TCR of each sample is randomly sampled without replacement, so that the total number of CDR3 sequences of each sample is 30,000. For any specific CDR3 sequence X, the number of repeated occurrences in the single-sample sequ...

Embodiment 2

[0086] Verify the specificity of the liver cancer TCR marker CDR3 sequence set:

[0087] 1. Sampling and immune map analysis

[0088] Peripheral blood (10mL per person) was collected from 335 non-hepatic cancer patients and 4 subjects with unknown health status, and the amino acid sequences of the TCR epitope 3 (CDR3) of the subjects and the control group were obtained by high-throughput sequencing , to ensure that the total number of functional TCR CDR3 sequences of each sample is not less than 30,000; random non-replacement sampling is performed on the TCR CDR3 sequences of each sample, so that the total number of CDR3 sequences of each sample is 30,000.

[0089] 2. Randomly select 100 healthy people and 45 non-tumor disease patients from the control group in Example 1.

[0090] 3. According to the immune profiles of 100 healthy people, 45 non-tumor disease patients, and 10 liver cancer patients from Example 1, and 335 non-liver cancer tumor patients and 4 subjects with unk...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a peripheral blood TCR marker for liver cancer as well as a detection kit and application thereof. The marker comprises at least one of proteins shown in a sequence Spec Seq 1-100. The TCR marker is based on a high-throughput sequencing method; wherein only a small amount of peripheral blood needs to be adopted for extracting RNA, then an immune map library is established by processing a sample, a characteristic TCR sequence in the liver cancer peripheral blood is determined firstly through high-throughput sequencing and TCR data analysis, and then a test result of a sample to be tested is compared with the characteristic TCR sequence, so that whether the liver cancer exists or not is determined. The TCR marker can simultaneously compare a huge number of liver cancer specific TCR sequences, has higher specificity and accuracy compared with single detection of one or more markers, thus improving the diagnosis efficiency.

Description

technical field [0001] The invention belongs to the technical field of gene detection, and in particular relates to a liver cancer peripheral blood TCR marker, a detection kit and application thereof. Background technique [0002] According to the latest statistics from the World Health Organization in 2018, liver cancer is one of the most common malignant tumors in the world, ranking first in the incidence of various cancers (4.7%) and fourth in the proportion of cancer deaths (8.2%) ). China is a big country with liver cancer, its incidence rate ranks fourth among malignant tumors in the country, and its mortality rate ranks second among malignant tumors. Although there are many treatment methods for liver cancer, the actual benefits for patients are very limited. A large-scale domestic study included 1,330 patients with hepatocellular carcinoma. The 5-year survival rate after surgery was 36.9%, and the recurrence rate was 61.5%. Even for small liver cancer, the 5-year r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574A61K39/00A61P35/00
CPCG01N33/57438G01N33/57488A61K39/001111A61P35/00G01N2333/7051
Inventor 张志新卓越杨鑫文学平何彭铭
Owner CHENGDU EXAB BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com